Unplanned hospital readmissions following HeartMate 3 implantation: Readmission rates, causes, and impact on survival

Author:

Shih Hueyjong1,Mondellini Giulio M.2,Kurlansky Paul A.13,Sun Jocelyn3,Ning Yuming3,Feldman Vivian R.2,Tiburcio Melie2,Maguire Conor W.2,Ladanyi Annamaria2,Clerkin Kevin2,Naka Yoshifumi1,Sayer Gabriel T.2,Uriel Nir2,Colombo Paolo C.2,Takeda Koji1,Yuzefpolskaya Melana2ORCID

Affiliation:

1. Department of Surgery, Division of Cardiothoracic and Vascular Surgery Columbia University Medical Center New York New York USA

2. Division of Cardiovascular Medicine, Department of Cardiology, New York Presbyterian Hospital Columbia University New York New York USA

3. Center for Innovation and Outcomes Research, Department of Surgery Columbia University New York New York USA

Abstract

AbstractBackgroundHospital readmissions following left ventricular assist device (LVAD) remain a frequent comorbidity, associated with decreased quality of life and increased resources utilization. This study sought to determine causes, predictors, and impact on survival of hospitalizations during HeartMate 3 (HM3) support.MethodsAll patients implanted with HM3 between November 2014 to December 2019 at Columbia University Irving Medical Center were consecutively enrolled in the study. Demographics and clinical characteristics from the index admission and the first outpatient visit were collected and used to estimate 1‐year and 900‐day readmission‐free survival and overall survival. Multivariable analysis was performed for subsequent readmissions.ResultsOf 182 patients who received a HM3 LVAD, 167 (92%) were discharged after index admission and experienced 407 unplanned readmissions over the median follow up of 727 (interquartile range (IQR): 410.5, 1124.5) days. One‐year and 900‐day mean cumulative number of all‐cause unplanned readmissions was 0.43 (95%CI, 0.36, 0.51) and 1.13 (95%CI, 0.99, 1.29). The most frequent causes of rehospitalizations included major infections (29.3%), bleeding (13.2%), device‐related (12.5%), volume overload (7.1%), and other (28%). One‐year and 900‐day survival free from all‐cause readmission was 38% (95%CI, 31–46%) and 16.6% (95%CI, 10.3–24.4%). One‐year and 900‐day freedom from 2, 3, and ≥4 readmissions were 60.7%, 74%, 74.5% and 26.2%, 33.3%, 41.3%. One‐year and 900‐day survival were unaffected by the number of readmissions and remained >90%. Male sex, ischemic etiology, diabetes, lower serum creatinine, longer duration of index hospitalization, and a history of readmission between discharge and the first outpatient visit were associated with subsequent readmissions.ConclusionsUnplanned hospital readmissions after HM3 are common, with infections and bleeding accounting for the majority of readmissions. Irrespective of the number of readmissions, one‐year survival remained unaffected.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3